These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30464762)

  • 1. Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing.
    Campillo-Davo D; Fujiki F; Van den Bergh JMJ; De Reu H; Smits ELJM; Goossens H; Sugiyama H; Lion E; Berneman ZN; Van Tendeloo V
    Front Immunol; 2018; 9():2503. PubMed ID: 30464762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
    Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
    Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer.
    Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki AM; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
    Eur J Immunol; 2019 Aug; 49(8):1278-1290. PubMed ID: 31054264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.
    Okamoto S; Mineno J; Ikeda H; Fujiwara H; Yasukawa M; Shiku H; Kato I
    Cancer Res; 2009 Dec; 69(23):9003-11. PubMed ID: 19903853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
    Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
    Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
    Xu Y; Morales AJ; Cargill MJ; Towlerton AMH; Coffey DG; Warren EH; Tykodi SS
    Cancer Immunol Immunother; 2019 Dec; 68(12):1979-1993. PubMed ID: 31686124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.
    Hiasa A; Nishikawa H; Hirayama M; Kitano S; Okamoto S; Chono H; Yu SS; Mineno J; Tanaka Y; Minato N; Kato I; Shiku H
    Gene Ther; 2009 May; 16(5):620-8. PubMed ID: 19242528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T Cell Receptor Engineered Lymphocytes for Cancer Therapy.
    Rollins MR; Spartz EJ; Stromnes IM
    Curr Protoc Immunol; 2020 Jun; 129(1):e97. PubMed ID: 32432843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
    Shirakura Y; Mizuno Y; Wang L; Imai N; Amaike C; Sato E; Ito M; Nukaya I; Mineno J; Takesako K; Ikeda H; Shiku H
    Cancer Sci; 2012 Jan; 103(1):17-25. PubMed ID: 21951605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
    Sharma P; Kranz DM
    Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
    Berdien B; Reinhard H; Meyer S; Spöck S; Kröger N; Atanackovic D; Fehse B
    Hum Vaccin Immunother; 2013 Jun; 9(6):1205-16. PubMed ID: 23428899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
    Tan AT; Yang N; Lee Krishnamoorthy T; Oei V; Chua A; Zhao X; Tan HS; Chia A; Le Bert N; Low D; Tan HK; Kumar R; Irani FG; Ho ZZ; Zhang Q; Guccione E; Wai LE; Koh S; Hwang W; Chow WC; Bertoletti A
    Gastroenterology; 2019 May; 156(6):1862-1876.e9. PubMed ID: 30711630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer.
    Berdien B; Mock U; Atanackovic D; Fehse B
    Gene Ther; 2014 Jun; 21(6):539-48. PubMed ID: 24670996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human adenovirus-specific γ/δ and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation.
    Dörrie J; Krug C; Hofmann C; Müller I; Wellner V; Knippertz I; Schierer S; Thomas S; Zipperer E; Printz D; Fritsch G; Schuler G; Schaft N; Geyeregger R
    PLoS One; 2014; 9(10):e109944. PubMed ID: 25289687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leucocyte antigen class I-redirected anti-tumour CD4
    Tan MP; Dolton GM; Gerry AB; Brewer JE; Bennett AD; Pumphrey NJ; Jakobsen BK; Sewell AK
    Clin Exp Immunol; 2017 Jan; 187(1):124-137. PubMed ID: 27324616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.
    Birkholz K; Hombach A; Krug C; Reuter S; Kershaw M; Kämpgen E; Schuler G; Abken H; Schaft N; Dörrie J
    Gene Ther; 2009 May; 16(5):596-604. PubMed ID: 19158846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.
    Knies D; Klobuch S; Xue SA; Birtel M; Echchannaoui H; Yildiz O; Omokoko T; Guillaume P; Romero P; Stauss H; Sahin U; Herr W; Theobald M; Thomas S; Voss RH
    Oncotarget; 2016 Apr; 7(16):21199-221. PubMed ID: 27028870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TCR-engineered T cells to treat tumors: Seeing but not touching?
    Debets R; Donnadieu E; Chouaib S; Coukos G
    Semin Immunol; 2016 Feb; 28(1):10-21. PubMed ID: 26997556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.